-
Special Review
-
Korean J Med. 2014;87(1):19-25. Published online July 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.87.1.19
- Peroxisome Proliferator-Activated Receptor (PPAR) α/γ 작용제
-
이지현
-
대구가톨릭대학교 의과대학 내과학교실
- Peroxisome Proliferator-Activated Receptor (PPAR) α/γ Agonist
-
Jihyun Lee
-
Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
- Corresponding author: Jihyun Lee ,Tel: +82-53-650-4051, Fax: +82-53-651-4009, Email: jhlee9@cu.ac.kr
-
- Abstract
- Peroxisome proliferator-activated receptor (PPAR) agonists improve glucose control and insulin sensitivity, reduce concentrations
of atherogenic lipoproteins, and decrease circulating levels of inflammatory mediators. PPAR activation is considered an
important pharmacologic target for patients with type 2 diabetes. However, the PPAR agonists in clinical use have undesirable side
effects, including weight gain, heart failure, and bone fractures. PPAR α/γ dual agonists each target one or more of the key cardiometabolic
risk factors of diabetic dyslipidemia, insulin resistance, hyperglycemia, and inflammation; thus, combining their benefits
to provide glucose control and ameliorate cardiovascular risks has emerged as an attractive treatment option. Aleglitazar,
which was designed to balance the activation of PPAR α/γ, proved efficacious in improving glycemic control and lipid homeostasis
and is anticipated to minimize PPAR-related side effects. Whether the effects of aleglitazar on cardiometabolic risk factors translate
into improved cardiovascular outcomes, particularly in high-risk patients, is currently being evaluated by AleCardio, a large,
long-term, time-, and event-driven outcome study of type 2 diabetics with recent acute coronary syndrome.
Keywords :PPAR α/γ agonist, Diabetic dyslipidemia, Insulin resistance, Aleglitazar
